Introduction {#sec1-1}
============

Gastrointestinal cancer (GI) mention to malignant conditions of the gastrointestinal tract including the esophagus, stomach, colon and rectum. Esophageal, gastric and colorectal cancers are the sixth, third and second most common cause of cancer-related death, respectively (Torre et al., 2015). Despite the advancement of diagnostic methods, surgical techniques and medical treatment, the cancer-related mortality remained high due to the invasion and metastasis of tumor at the time of diagnosis(Redig and McAllister, 2013). A majority of studies suggest pathogenesis of cancer is influenced by multiple environmental factors, genetic susceptibility and acquired susceptibility (Yang et al., 2015). Allelic variations in oncogenes are nomination genetic risk factors that may vary the onset and outcome of GI cancer. There has been evidence that human susceptibility to cancer could be influenced by single nucleotide polymorphisms (SNPs) located in DNA repair genes (Chiurillo, 2014).

Homologous recombination is one of the DNA repair mechanisms and the gene encoding X-ray repair cross-complementing group 3 (XRCC3) encodes a member of the RecA/Rad51-related protein family that contributes in homologous recombination to retain chromosome stability and repair DNA damage (Moynahan, 2010). XRCC3 gene is located on chromosome 14q32.3 and consists of 21670 base pair. This gene codifies a mature polypeptide with 346 amino acids (Talar-Wojnarowska et al., 2016). Many studies have demonstrated the role of X-ray repair cross-complementing group in cancer.

Abnormal activity or expression of XRCC3 reported in many types of cancer, like gastric, breast, ovarian and cervix cancer has been suggested as an important marker in tumorigenesis (Abdel-Fatah et al., 2013; Bajpai et al., 2013; Engin, 2013; Sultana et al., 2013). Many single nucleotide polymorphisms in the XRCC3 gene have been reported. Moreover, a common polymorphism in XRCC3 gene is at nucleotide 1,8607C/T (rs861,539) that results in substitution of amino acid threonine to methionine at codon 241 (Thr241Met) in exon seven of XRCC3 gene. Inherited functional polymorphisms in DNA repair genes may influence the capacity of DNA repair process, thus leading to increased cancer risk (Aka et al., 2004).

To date, several case-control studies have been conducted to assess the role of XRCC3 Thr241Met polymorphism in predisposition to GI cancer but the published results are controversial and inconsistent. In 2006, Huang et al. found that gastric cancer occurrence was associated with the XRCC3 Met/Met polymorphic variant (OR=1.8, 95% CI=1.1-2.9 for TT genotype) in a Chinese population (Huang et al., 2006) and Mucha et al. (2013) suggested significant association of heterozygotes (OR=0.6, 95% CI=0.4-0.9) and the Met allele (OR=0.7, 95% CI=0.5-0.9) with reduced colorectal cancer risk (Mucha et al., 2013). However, in 2010, Palli et al. reported that XRCC3 Thr241Met polymorphism may not play a significant role in the risk of gastric cancer in Italian population (OR=0.8 and 95% CI= 0.7--1.78 for TT genotype) (Palli et al., 2010)and Moghtit et al. (2014) suggested that the XRCC3 Thr241Met polymorphism may not be associated with the colorectal cancer risk in West Algerian population (Moghtit et al., 2014). We carried out an updated meta-analysis of all available case--control literatures applying multiple genetic statistical models to gain a more reliable conclusion. Besides, stratified analysis by Hardy-Weinberg equilibrium (HWE), ethnicity, source of controls and cancer type were also accomplished for further study.

Materials and Methods {#sec1-2}
=====================

Identification of eligible studies {#sec2-1}
----------------------------------

A literature research was conducted using PubMed Database updated on March 2016 for all publications on the association between XRCC3 Thr241Met polymorphism and GI cancer susceptibility. The search strategy was performed by combination of the following keywords: polymorphism, Thr241Met, XRCC3, esophageal, gastric, colorectal, carcinoma and cancer. All eligible studies were retrieved and their references were reviewed for other eligible studies. The literature retrieval was carried out in duplication by independent investigators.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

The eligible studies included in present meta-analysis had to comprise all the following inclusion criteria: (a) the study was published in English, (b) case-control studies about the association of XRCC3 Thr241Met polymorphism with GI cancer risk, (c) the study provided sufficient genotype distribution data to compute odds ratios (ORs) and 95% confidence intervals (CIs). Studies such as letters, review, case reports, case-only studies, unpublished data and duplicated studies must be excluded.

Data extraction {#sec2-3}
---------------

Data extracted from relevant articles comprised the first author's name, country of origin, year of publication, ethnicity, number of cases and controls, genotype frequencies for cases and controls and Hardy-Weinberg equilibrium (HWE) for controls (P value). To ensure the accuracy of the extracted data, the investigators reviewed the information extraction results and reached consensus on all of the data extracted.

Statistical analysis {#sec2-4}
--------------------

The HWE of genotypes distribution in the control group was assessed by chi-square test and deviation was considered when P \<0.05. The risk of GI cancer associated with the XRCC3 Thr241Met polymorphism was estimated for each study by the odds ratio (OR) and 95.0% confidence interval (CI) under the Allelic model (T vs. C), heterozygote model (CT vs. CC), homozygote model (TT vs. CC), dominant model (TT+ CT vs. CC) and recessive model (TT vs. CT+CC). The significance of the pooled OR was evaluated with the Z test, and it was considered statistically significant for P \<0.05. Subgroup analyses were conducted based on ethnicity, source of controls and cancer type. Heterogeneity assumption was checked by a chi-square-based Q test, and the index I2 was used to quantify the effect of heterogeneity (Higgins and Thompson, 2002). A p-value of \>0.1 for the Q-test or I^2^ \<40.0% demonstrated a lack of heterogeneity among different studies; so that the combined OR estimate of each study was computed by the fixed-effects model. Otherwise, the random-effects model was used (DerSimonian and Laird, 1986). In order to confirm the stability and reliability of our combined results in the meta-analysis, a sensitivity analysis was conducted by sequential deletion of a individual study. Begg's funnel plots and Egger's linear regression test were used to estimate of publication bias. Funnel plot asymmetry was further assessed by the method of Egger's linear regression test (P \<0.05 was determined a significant publication bias) (Song et al., 2002). Statistical analysis was conducted using Comprehensive Meta-Analysis software (version 2.2)

Results {#sec1-3}
=======

Characteristics of included studies {#sec2-5}
-----------------------------------

Relevant articles published before March 1st, 2016 were identified through a search in PubMed database. Flow chart of the study selection process was illustrated in [Figure 1](#F1){ref-type="fig"} Based on the search criteria, 7,649.0 multiple cancer cases and 11,123.0 controls from 28.0 eligible articles with 30.0 studies were recruited for this meta-analysis.(Krupa and Blasiak, 2004; Shen et al., 2004; Tranah et al., 2004; Casson et al., 2005; Duarte et al., 2005; Huang et al., 2005; Jin et al., 2005; Stern et al., 2005; Yeh et al., 2005; Huang et al., 2006; Moreno et al., 2006; Skjelbred et al., 2006; Ye et al., 2006; Ruzzo et al., 2007; Improta et al., 2008; Pardini et al., 2008; Canbay et al., 2010; Palli et al., 2010; Wang et al., 2010; Canbay et al., 2011; Krupa et al., 2011; Zhao et al., 2011; Gil et al., 2012; Zhao et al., 2012; Djansugurova et al., 2013; Mucha et al., 2013; Moghtit et al., 2014; Nissar et al., 2014; Cheng et al., 2015). One of the articles included gastric cancer and two types of esophageal cancer (Ye et al., 2006). Eight of eligible articles deviated from HWE (Krupa and Blasiak, 2004; Jin et al., 2005; Stern et al., 2005; Canbay et al., 2011; Krupa et al., 2011; Zhao et al., 2011; Zhao et al., 2012; Nissar et al., 2014) among these publications, 19 studies were conducted in Caucasian descent (Krupa and Blasiak, 2004; Tranah et al., 2004; Casson et al., 2005; Huang et al., 2005; Moreno et al., 2006; Skjelbred et al., 2006; Ye et al., 2006; Ruzzo et al., 2007; Improta et al., 2008; Canbay et al., 2010; Palli et al., 2010; Canbay et al., 2011; Krupa et al., 2011; Gil et al., 2012; Djansugurova et al., 2013; Mucha et al., 2013; Moghtit et al., 2014), and nine studies were performed in Asian descent (Shen et al., 2004; Jin et al., 2005; Yeh et al., 2005; Huang et al., 2006; Wang et al., 2010; Zhao et al., 2011; Zhao et al., 2012; Nissar et al., 2014; Cheng et al., 2015). There were 15 hospital-based case--control studies (Casson et al., 2005; Duarte et al., 2005; Yeh et al., 2005; Huang et al., 2006; Moreno et al., 2006; Ruzzo et al., 2007; Improta et al., 2008; Canbay et al., 2010; Krupa et al., 2011; Zhao et al., 2011; Gil et al., 2012; Zhao et al., 2012; Djansugurova et al., 2013; Mucha et al., 2013) involving 3,644 cases and 4,540 controls and 15 population based case--control studies (Shen et al., 2004; Tranah et al., 2004; Huang et al., 2005; Jin et al., 2005; Stern et al., 2005; Skjelbred et al., 2006; Ye et al., 2006; Palli et al., 2010; Wang et al., 2010; Canbay et al., 2011; Moghtit et al., 2014; Nissar et al., 2014; Cheng et al., 2015) including 4,005 cases and 6,583 controls in current meta-analysis. For the meta-analysis of XRCC3 Thr241Met polymorphism for GI cancer, there were four studies on esophageal cancer (Casson et al., 2005; Ye et al., 2006; Djansugurova et al., 2013), 10 studies on gastric cancer (Shen et al., 2004; Duarte et al., 2005; Huang et al., 2005; Huang et al., 2006; Ye et al., 2006; Ruzzo et al., 2007; Canbay et al., 2010; Palli et al., 2010; Zhao et al., 2011; Cheng et al., 2015), and 16 study on colorectal cancer (Krupa and Blasiak, 2004; Tranah et al., 2004; Jin et al., 2005; Stern et al., 2005; Yeh et al., 2005; Moreno et al., 2006; Skjelbred et al., 2006; Improta et al., 2008; Wang et al., 2010; Canbay et al., 2011; Krupa et al., 2011; Gil et al., 2012; Zhao et al., 2012; Mucha et al., 2013; Moghtit et al., 2014; Nissar et al., 2014). The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was the most common technique used for the genotype analyzing. All the articles were written in English and the data collected from the eligible studies were summarized in [Table 1](#T1){ref-type="table"}.

![Flow Chart of Study Selection in the Meta-analysis](APJCP-17-4599-g001){#F1}

###### 

General Characteristics of Studies Included in the Meta-Analysis

  Cancer location     First author        Year   Country      Ethnicity   Source of controls   Cases   Controls   Genotyping method   P HWE
  ------------------- ------------------- ------ ------------ ----------- -------------------- ------- ---------- ------------------- ---------
  Esophageal cancer   Djansugurova        2013   Kazakhstan   Caucasian   HB                   115.0   100.0      PCR-RFLP            0.108
                      Ye (1)              2006   Sweden       Caucasian   PB                   96.0    472.0      PCR-RFLP            0.506
                      Ye (2)              2006   Sweden       Caucasian   PB                   81.0    472.0      PCR-RFLP            0.506
                      Casson              2005   Canada       Caucasian   HB                   56.0    95.0       PCR-RFLP            0.748
  Gastric cancer      Shidan              2015   China        Asian       PB                   440.0   602.0      PCR-LDR             0.841
                      Zhao L              2011   China        Asian       HB                   721.0   989.0      TaqMan              \<0.001
                      Canbay              2010   Turkey       Caucasian   HB                   40.0    247.0      PCR-RFLP            0.861
                      Palli               2010   Italy        Caucasian   PB                   294.0   546.0      TaqMan              0.713
                      Ruzzo               2007   Italy        Caucasian   HB                   90.0    121.0      PCR-RFLP            0.214
                      Ye (3)              2006   Sweden       Caucasian   PB                   126.0   472.0      PCR-RFLP            0.506
                      Huang GP            2006   China        Asian       HB                   309.0   188.0      PCR-RFLP            0.946
                      Huang WY            2005   Poland       Caucasian   PB                   281.0   390.0      PCR-RFLP            0.138
                      Duarte              2005   Brazil       Others      HB                   160.0   150.0      PCR-RFLP            0.127
                      Shen                2004   China        Asian       PB                   188.0   166.0      PCR-RFLP            0.514
  Colorectal cancer   Nissar              2014   Kashmir      Asian       PB                   120.0   150.0      PCR-RFLP            \<0.001
                      Moghtit             2014   Algeria      Caucasian   PB                   129.0   148.0      Sequencing          0.741
                      Mucha               2013   Poland       Caucasian   HB                   194.0   209.0      PCR-RFLP            0.317
                      Zhao Y              2012   China        Asian       HB                   485.0   970.0      PCR-CTPP            \<0.001
                      Gil                 2012   Poland       Caucasian   HB                   132.0   100.0      PCR-RFLP            0.113
                      Krupa               2011   Poland       Caucasian   HB                   100.0   100.0      PCR-RFLP            0.039
                      Canbay E            2011   Turkey       Caucasian   PB                   79.0    247.0      PCR-RFLP            \<0.001
                      Wang                2010   India        Asian       PB                   302.0   291.0      PCR-RFLP            0.963
                      Improta             2008   Italy        Caucasian   HB                   109.0   121.0      PCR-RFLP            0.978
                      Moreno              2006   spain        Caucasian   HB                   361.0   316.0      APEX                0.447
                      Skjelbred           2006   Norwegian    Caucasian   PB                   157.0   399.0      TaqMan              0.342
                      Jin                 2005   China        Asian       PB                   140.0   280.0      PCR-RFLP            0.025
                      Yeh                 2005   Taiwan       Asian       HB                   721.0   734.0      PCR-RFLP            0.958
                      Stern               2005   USA          Mixed       PB                   737.0   787.0      PCR-RFLP            0.033
                      Krupa and blasiak   2004   Poland       Caucasian   HB                   51.0    100.0      PCR-RFLP            \<0.001
                      Tranah              2004   UK           Caucasian   PB                   835.0   1161.0     TaqMan              0.508

HB, hospital-based; PB, population-based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphisms; PCR-CTPP, polymerase chain reaction-the confronting-two-pair primer; APEX, arrayed primer extension; HWE, Hardy-Weinberg equilibrium

Main results {#sec2-6}
------------

[Table 2](#T2){ref-type="table"} listed the main results of the association between XRCC3 polymorphism and GI cancer risk. The overall results of meta-analysis showed borderline association between the XRCC3 Thr241Met polymorphism and increased GI cancer susceptibility in allelic and recessive genetic models (T vs. C: OR=1.2, 95 % CI=1.0--1.4, POR=0.04; TT vs. CT+CC: OR=1.3, 95 % CI=1.04-1.6, POR=0.04). However, there was no obvious association between XRCC3Thr194Met polymorphism and GI cancer risk under the homozygous, heterozygous and dominant genetic models (TT vs. CC: OR=1.3, 95 % CI=0.9--1.7, POR=0.07; CT vs. CC: OR=1.1, 95 % CI=0.9--1.3, POR=0.22; TT+CT vs. CC: OR=1.1, 95 % CI=0.9--1.4, POR=0.17; [Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"})

###### 

Investigating the Association between XRCC3 Thr241Met Polymorphism and Gastrointestinal Cancer in Overall Studies

                      Test of association 95% CI   Test of heterogeneity                                                     
  ------------------- ---------------------------- ----------------------- ---------- ------ ----- ----- --------- --------- ---------
  Overall             30.0                         7,649.0                 11,123.0                                          
  T vs. C                                                                             1.2    1.0   1.4   0.038     \<0.001   87.9
  TT vs. CC                                                                           1.3    1.0   1.7   0.072     \<0.001   77.9
  CT vs. CC                                                                           1.1    0.9   1.4   0.223     \<0.001   82.7
  TT+CT vs. CC                                                                        1.2    0.9   1.4   0.169     \<0.001   86.7
  TT vs. CT+CC                                                                        1.3    1.0   1.6   0.042     \<0.001   70.1
  HWE in controls                                                                                                            
  YES                 22.0                         5,216.0                 7,500.0                                           
  T vs. C                                                                             1.0    0.9   1.1   0.965     0.01      46.0
  TT vs. CC                                                                           1.0    0.8   1.2   0.98      0.08      31.4
  CT vs. CC                                                                           1.0    0.9   1.1   0.537     0.008     47.4
  TT+CT vs. CC                                                                        1.0    0.9   1.1   0.649     \<0.001   57.2
  TT vs. CT+CC                                                                        1.0    0.9   1.1   0.722     0.248     16.0
  NO                  8.0                          2,433.0                 3,623.0                                           
  T vs. C                                                                             1.8    1.2   2.7   0.003     \<0.001   93.6
  TT vs. CC                                                                           2.5    1.3   4.9   0.009     \<0.001   88.0
  CT vs. CC                                                                           1.9    1.2   3.0   0.007     \<0.001   89.8
  TT+CT vs. CC                                                                        2.0    1.2   3.2   0.006     \<0.001   92.3
  TT vs. CT+CC                                                                        2.1    1.3   3.6   0.005     \<0.001   83.4
  Ethnicity                                                                                                                  
  Asian               9.0.                         3,423.0                 4,370.0                                           
  T vs. C                                                                             1.5    1.1   2.1   0.009     \<0.001   82.9
  TT vs. CC                                                                           2.1    1.3   3.4   0.004     0.008     61.1
  CT vs. CC                                                                           1.6    1.1   2.4   0.014     \<0.001   88.0
  TT+CT vs. CC                                                                        1.6    1.1   2.4   0.014     \<0.001   90.1
  TT vs. CT+CC                                                                        2.2    1.8   2.7   \<0.001   0.416     2.2
  Caucasian           19.0                         3,326.0                 5,816.0                                           
  T vs. C                                                                             1.1    0.9   1.2   0.364     \<0.001   61.4
  TT vs. CC                                                                           1.1    0.9   1.4   0.454     0.002     54.6
  CT vs. CC                                                                           1.0    0.8   1.1   0\. 694   0.015     46.0
  TT+CT vs. CC                                                                        1.0    0.8   1.2   0.887     0.001     59.2
  TT vs. CT+CC                                                                        1.2    0.9   1.5   0.234     \<0.001   63.7
  Source of control                                                                                                          
  HB                  15.0                         3,644.0                 4,540.0                                           
  T vs. C                                                                             1.3    1.0   1.6   0.117     \<0.001   91.1
  TT vs. CC                                                                           1.6    1.0   2.6   0.049     \<0.001   83.1
  CT vs. CC                                                                           1.1    0.8   1.5   0.7       \<0.001   89.3
  TT+CT vs. CC                                                                        1.2    0.8   1.7   0.476     \<0.001   91.4
  TT vs. CT+CC                                                                        1.6    1.1   2.4   0.013     \<0.001   75.8
  PB                  15.0                         4,005.0                 6,583.0                                           
  T vs. C                                                                             1.1    0.9   1.2   0.38      0.012     50.8
  TT vs. CC                                                                           0.95   0.8   1.1   0.5       0.654     \<0.001
  CT vs. CC                                                                           1.1    0.9   1.2   0.2       0.066     38.3
  TT+CT vs. CC                                                                        1.02   0.9   1.1   0.6       0.024     46.7
  TT vs. CT+CC                                                                        0.9    0.8   1.1   0.4       0.839     \<0.001
  Cancer type                                                                                                                
  Esophageal cancer   4.0                          348.0                   1139.0                                            
  T vs. C                                                                             1.1    0.9   1.3   0.34      0.884     \<0.001
  TT vs. CC                                                                           1.3    0.8   2.1   0.221     0.478     \<0.001
  CT vs. CC                                                                           0.8    0.5   1.4   0.415     0.023     68.4
  TT+CT vs. CC                                                                        0.9    0.7   1.2   0.665     0.003     78.8
  TT vs. CT+CC                                                                        1.2    0.8   1.9   0.365     0.354     7.75
  Gastric cancer      10.0                         2253.0                  3871.0                                            
  T vs. C                                                                             1.1    0.8   1.6   0.504     \<0.001   92.2
  TT vs. CC                                                                           1.2    0.7   2.2   0.561     \<0.001   86.7
  CT vs. CC                                                                           1.1    0.8   1.6   0.493     \<0.001   86.8
  TT+CT vs. CC                                                                        1.1    0.8   1.7   0.538     \<0.001   90.6
  TT vs. CT+CC                                                                        1.1    0.7   1.8   0.6       \<0.001   77.9
  Colorectal cancer   16.0                         4652.0                  6113.0                                            
  T vs. C                                                                             1.2    1.0   1.5   0.033     \<0.001   85.4
  TT vs. CC                                                                           1.3    0.9   1.7   0.14      \<0.001   68.1
  CT vs. CC                                                                           1.2    1.0   1.5   0.144     \<0.001   78.5
  TT+CT vs. CC                                                                        1.2    1.0   1.5   0.1       \<0.001   82.1
  TT vs. CT+CC                                                                        1.1    1.0   1.3   0.139     \<0.001   69.4

![Forest Plot of Associations between XRCC3 Thr241Met Polymorphism and GI Cancer Risk. A: Allelic Model (T vs. C); B: Heterozygous model (TT vs. CC)](APJCP-17-4599-g002){#F2}

Stratified analyses were also performed by ethnicities, sources of controls, cancer location and HWE.

Stratified analysis by ethnicity, source of controls and cancer type detected some associations between Thr241Met polymorphism and cancer susceptibility.

In stratified analysis by ethnicity, the present meta-analysis showed that the Thr241Met polymorphism was associated with increased GI cancer risk in Asians (T vs. C: OR =1.5, 95 % CI=1.1--2.1, POR=0.009; TT vs. CC: OR=2.1, 95 % CI=1.2--3.4, POR=0.004; CT vs. CC: OR=1.6, 95 % CI=1.1--2.4, POR=0.014; TT+CT vs. CC: OR=1.6, 95 % CI=1.1--2.4, POR=0.014; TT vs. CT+CC: OR=2.2, 95 % CI=1.8--2.7, POR\<0.001)

In stratified analysis according to source of control, significant increased GI cancer risk was found in hospital-based studies (TT vs. CC: OR=1.6, 95 % CI=1.0--2.6, POR=0.049; TT vs. CT+CC: OR=1.6, 95 % CI=1.1-2.3, POR=0.013), but not in population-based studies.

In subgroup analysis by cancer type, significant increased GI cancer risk was observed in colorectal cancer (T vs. C: OR=1.2, 95 % CI=1.0--1.5, POR=0.033), but not in esophageal and gastric cancer ([Table 2](#T2){ref-type="table"} and [Figure 3](#F3){ref-type="fig"}).

![Forest Plot of Subgroup Analysis by Ethnicity and HWE on the Association between XRCC3 Thr241Met Polymorphism and GI Cancer Risk. A: dominant model of Ethnicity Subgroup (TT+CT vs. CC); B: Recessive model of HWE Subgroup (TT vs. CT+CC)](APJCP-17-4599-g003){#F3}

When limiting the meta-analysis to the 22.0 studies conforming to HWE, the results altered and no statistical significant association found in all genetic models. In addition, studies conforming to HWE stratified by ethnicity, source of controls and cancer type. Statistical analysis demonstrated no significant association between Thr241Met XRCC3 and GI cancer in all genetic models ([Table 3](#T3){ref-type="table"}).

###### 

Investigating the Association between XRCC3 Thr241Met Polymorphism and Gastrointestinal Cancer in Studies Conforming HWE

                           Test of association 95% CI   Test of heterogeneity                                                 
  ------------------------ ---------------------------- ----------------------- --------- ----- ----- ----- ------- --------- ---------
  Studies conforming HWE   22.0                         5,216.0                 7,500.0                                       
  T vs. C                                                                                 1.0   0.9   1.1   0.965   0.01      46.0
  TT vs. CC                                                                               1.0   0.8   1.2   0.98    0.08      31.4
  CT vs. CC                                                                               1.0   0.9   1.1   0.537   0.008     47.4
  TT+CT vs. CC                                                                            1.0   0.9   1.1   0.649   \<0.001   57.2
  TT vs. CT+CC                                                                            1.0   0.9   1.1   0.722   0.248     16.0
  Asian                    5.0                          1,960.0                 1,981.0                                       
  T vs. C                                                                                 1.1   0.9   1.4   0.5     0.063     55.3
  TT vs. CC                                                                               1.3   0.8   2.3   0.304   0.449     \<0.001
  CT vs. CC                                                                               1.1   0.8   1.4   0.599   0.074     53.2
  TT+CT vs. CC                                                                            1.1   0.8   1.5   0.536   0.049     58.1
  TT vs. CT+CC                                                                            1.3   0.8   2.3   0.341   0.881     \<0.001
  Caucasian                16.0                         3,096.0                 5,369.0                                       
  T vs. C                                                                                 1.0   0.9   1.1   0.984   0.028     44.7
  TT vs. CC                                                                               1.0   0.8   1.2   0.985   0.041     41.6
  CT vs. CC                                                                               1.0   0.8   1.1   0.563   0.029     44.5
  TT+CT vs. CC                                                                            1.0   0.8   1.1   0.666   0.002     57.4
  TT vs. CT+CC                                                                            1.0   0.8   1.2   0.954   0.08      35.3
  HB                       11.0                         2,287.0                 2,381.0                                       
  T vs. C                                                                                 1.0   0.8   1.2   0.969   0.001     67.6
  TT vs. CC                                                                               1.1   0.8   1.7   0.57    0.008     58.2
  CT vs. CC                                                                               0.8   0.7   1.1   0.191   0.001     66.6
  TT+CT vs. CC                                                                            1.0   0.7   1.3   0.899   \<0.001   76.8
  TT vs. CT+CC                                                                            1.2   0.8   1.6   0.373   0.054     44.7
  PB                       11.0                         2,929.0                 5,119.0                                       
  T vs. C                                                                                 1.0   0.9   1.1   0.673   0.628     \<0.001
  TT vs. CC                                                                               0.9   0.8   1.1   0.356   0.82      \<0.001
  CT vs. CC                                                                               1.0   0.9   1.1   0.627   0.752     \<0.001
  TT+CT vs. CC                                                                            1.0   0.9   1.1   0.901   0.676     \<0.001
  TT vs. CT+CC                                                                            0.9   0.8   1.1   0.29    0.882     \<0.001
  Esophageal cancer        4.0                          348.0                   1,139.0                                       
  T vs. C                                                                                 1.1   0.9   1.3   0.34    0.884     \<0.001
  TT vs. CC                                                                               1.3   0.8   2.1   0.221   0.478     \<0.001
  CT vs. CC                                                                               0.8   0.5   1.4   0.415   0.023     68.4
  TT+CT vs. CC                                                                            0.9   0.7   1.2   0.665   0.003     78.8
  TT vs. CT+CC                                                                            1.2   0.8   1.9   0.365   0.354     7.8
  Gastric cancer           9.0                          1,928.0                 2,882.0                                       
  T vs. C                                                                                 1.0   0.9   1.1   0.793   0.106     39.3
  TT vs. CC                                                                               0.9   0.7   1.2   0.608   0.446     \<0.001
  CT vs. CC                                                                               1.1   0.9   1.2   0.323   0.142     34.4
  TT+CT vs. CC                                                                            1.0   0.9   1.2   0.749   0.09      41.6
  TT vs. CT+CC                                                                            0.9   0.8   1.2   0.526   0.639     \<0.001
  Colorectal cancer        9.0                          2,940.0                 3,479.0                                       
  T vs. C                                                                                 1.0   0.8   1.1   0.777   0.004     65.0
  TT vs. CC                                                                               1.0   0.7   1.4   0.925   0.02      55.9
  CT vs. CC                                                                               0.9   0.8   1.1   0.361   0.059     46.6
  TT+CT vs. CC                                                                            0.9   0.8   1.1   0.541   0.016     57.6
  TT vs. CT+CC                                                                            1.0   0.8   1.3   0.901   0.071     44.6

Publication bias {#sec2-7}
----------------

Publication bias of the selected studies was evaluated by the Begg's funnel plot and Egger's regression test. The funnel plot did not represent obvious asymmetry in any genetic model ([Figure 4](#F4){ref-type="fig"}). Similarly, no evidence of publication bias was observed by Egger's regression test (P=0.989 for allelic genetic model; P=0.803 for homozygous genetic model; P=0.527 for heterozygous genetic model; P=0.553 for dominant genetic model; P=0.511 for recessive genetic model). The results demonstrate lack of publication bias among all genetic models.

![Forest Plot of Association between XRCC3 Thr241Met Polymorphism and GI Cancer Risk. A: Homozygous genetic model (A vs. C); B: Heterozygous genetic model (AA vs. CC)](APJCP-17-4599-g004){#F4}

Test of heterogeneity {#sec2-8}
---------------------

Significant heterogeneity revealed among literatures for the XRCC3 Thr241Met polymorphism and GI cancer risk (allelic: P \<0.001, I^2^=87.9%; homozygous: P \<0.001, I^2^=77.9%; heterozygous: P \<0.001, I2=82.7%, dominant: P \<0.001, I^2^=86.7% and recessive: P \<0.001, I^2^=70.1). Hence, random-effect model was applied to generate CIs for these genetics models comparison (P \<0.05).

Sensitivity analysis {#sec2-9}
--------------------

Some studies with deviated from HWE, were included in this meta-analysis. Sensitivity analysis was performed to assess whether this deviation have an impact on the overall estimate. Sensitivity analysis was conducted by sequential deletion of single study to determine the influence of each individual study on the pooled OR and P-value for various genetic models. Individual studies involved in the meta-analysis were omitted and deletion of studies that deviated from HWE altered P-value of statistical significant associations. Also, sensitivity analysis was conducted in statistical results of studies conforming to HWE and statistical significances of the overall results did not alter. The sensitivity analysis confirmed the stability and reliability of the results.

Discussion {#sec1-4}
==========

Different DNA repair systems preserve the integrity of the human genome. DNA repair mechanisms are various and intricate, involving more than 100.0 genes (Sancar et al., 2004). Some important pathways in DNA repair have been characterize: nucleotide excision repair (NER), base excision repair (BER), and double-strand break repair (DSBR) (Christmann et al., 2003). Deficiency in the repair capacity because of polymorphisms or mutations in genes involved in DNA repair can ultimate genomic instability that lead to chromosomal instability syndromes and increased risk of developing different types of cancer (Manuguerra et al., 2006).

Double strand breaks (DSBs) are the most dangerous DNA damage and XRCC3 is required for the formation of the protein complex necessary for homologous recombination repair (HRR) of DNA DSB (Brenneman et al., 2000). The Thr241Met (T241M) is the most frequent polymorphism in XRCC3, resulting in the amino acid substitution of threonine to methionine in codon 241, which may modify the function of enzyme and its interaction with other proteins involved in the DNA repair mechanisms.

Mounting evidence by meta-analysis indicates that XRCC3 Thr241Met polymorphism is associated with risk of particularly cancer (e.g., melanoma skin cancer (Fan et al., 2015), prostate cancer (Xuan et al., 2015), lung cancer (Bei et al., 2015), and hepatocellular carcinoma (Wu et al., 2013). Several previous studies have evaluated the association between the XRCC3 Thr241Met polymorphism and GI cancer susceptibility; however, existing results are inconsistent. This meta-analysis was performed to derive a more precise estimation of the association between Thr241Met polymorphism and GI cancer risk.

The overall results indicated a borderline association between the Thr241Met polymorphism and increased GI cancer susceptibility in allelic and recessive genetic models. Subgroup analyses were carried out to further investigate the potential association. In stratified analysis by ethnicity, significant increased GI cancer susceptibility was found in Asians (all genetic models). However, no significant association was detected in Caucasians. The different effect of XRCC3 Thr241Met polymorphism between ethnicity may result from different genetic background and environmental exposures, which may contribute to the discrepancy. In stratified analysis according to source of control, significant increased GI cancer susceptibility was observed in hospital based studies (homozygous and recessive genetic models). The results of hospital-based case-control studies are not reliable because the controls from hospital-based studies may not be truly representative of general population. In subgroup analysis by cancer type, significant increased GI cancer risk was found in colorectal cancer (allelic genetic model).

Departure from HWE may be as a result of methodological and genetic reasons. Methodological reasons include genotyping errors or biased selection of subjects from the population and genetic reasons comprise non-random mating, or the alleles show recent mutations that have not reached equilibrium (Mitchell et al., 2003; Hosking et al., 2004). Because of the reasons of disequilibrium, the findings of genetic association studies might be counterfeit if the distribution of genotypes in the control groups were not in HWE (Salanti et al., 2005; Trikalinos et al., 2006). Hence, we excluded the studies that deviated from HWE in controls. When excluding the studies that deviated from HWE, a borderline association between XRCC3 polymorphism and GI cancer susceptibility altered in allelic and recessive genetic models in overall results. Also, all significant associations between XRCC3 Thr241Met and GI cancer in Asian, hospital based studies and colorectal cancer subgroup were disappeared.

Publication bias and sensitivity analysis were used in current meta-analysis to make our results more guaranteed. Both the Egger's test and Begg's funnel plot demonstrate no publication bias in this meta-analysis. Sensitivity analysis was conducted by sequential deletion of single study to determine the influence of each individual study on the pooled OR and P-value for various genetic models. Individual studies involved in the meta-analysis were omitted and deletion of studies that deviated from HWE altered P-value of statistical significant associations. Also, sensitivity analysis was conducted in statistical results of studies conforming to HWE and statistical significances of the overall results did not alter. The sensitivity analysis confirmed the stability and reliability of the results.

In interpreting results of the present meta-analysis, some limitations need to be considered. First, 7,649.0 cases and 11,123.0 controls were included in this meta-analysis; the sample size was relatively small and may not have provided sufficient statistical power to estimate the association between XRRC3 Thr241Met polymorphism and GI cancer risk. Therefore, more studies with a larger sample size are needed to prepare a more statistical analysis. Second, the original studies in the current meta-analysis mainly provided data towards Asians and Caucasians. Other ethnicities including Africans and mixed should be investigated to evaluation of probably association in future studies. In addition, Because of limited available data about association between XRCC3 Thr241Met polymorphism and GI cancer in Asian population and esophageal cancer, our results should be interpreted with caution. Larger and more studies are required to clarify the association of this polymorphism and risk of GI cancer in different ethnicities and cancer types. Third, the results of present meta-analysis were based on unadjusted estimates; data were not stratified by other factors such as gender, age, family history, smoking status, alcohol consumption and other lifestyle factors, because sufficient relevant information could not be extracted from the primary studies. Fourth, we did not conduct analyses on the potential role of gene-environment or gene--gene interactions because included studies did not provide usable data. Finally, it was difficult to achieve all articles published in various language and the studies published in English were included. Also, only published papers were included in current meta-analysis.

In spite of these limitations, our meta-analysis still has some advantages. According to our knowledge, this is the first meta-analysis to investigate the association of xrcc3 Thr241Met polymorphism with GI cancer, and the influence of this gene polymorphism on GI cancer susceptibility in different ethnic populations. The identified case-control studies in present meta-analysis were met our inclusion criteria. In addition, the methodological issues for meta-analysis, such as, stability of results, publication bias and heterogeneity were all well investigated.

In conclusion, present meta-analysis suggested that the XRCC3 Thr241Met polymorphism might influence GI cancer risk in Asians, although after removing studies not conforming to HWE, this association disappeared. Further studies with good design and larger sample sizes are required to provide a more precise estimation on the gene--gene or gene--environment interactions in the GI cancer.
